Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Soliris approved to treat neuromyelitis optica spectrum disorder

(HealthDay)—The U.S. Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday.

Soliris is indicated for intravenous use (300 mg/30 mL injection) in patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody-positive.

In a 48-week clinical study of 143 patients with NMOSD who were anti-AQP4-positive, patients randomly assigned to treatment with Soliris experienced a 94 percent reduction in NMOSD relapses compared with patients assigned to placebo. The need for hospitalizations and corticosteroid and plasma exchange treatment for acute attacks was also reduced with Soliris. The most frequently reported adverse reactions were upper respiratory infection, nasopharyngitis, diarrhea, back pain, dizziness, influenza, arthralgia, pharyngitis, and contusion.

A boxed warning label for Soliris indicates that patients treated with Soliris have had life-threatening and fatal meningococcal infections. The FDA notes that patients should be monitored for early signs of meningococcal infection, which should be recognized and treated early. Soliris is only available through the Risk Evaluation and Mitigation Strategy program. Prescribers should counsel patients about the risk for meningococcal infection and ensure they are vaccinated at least two weeks prior to the first administration of Soliris.

Approval was granted to Alexion Pharmaceuticals.

JUNE 28, 2019


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies